Su S F, Huang J D
Department of Clinical Pharmacy, National Cheng Kung University, Taiwan, Republic of China.
Drug Metab Dispos. 1996 Feb;24(2):142-7.
Digoxin-quinidine interaction is well documented in the literature. The mechanism is, however, unknown. Previously, it was shown that quinidine reduced digoxin secretion by inhibiting P-glycoprotein (Pgp) in the renal tubule. Because Pgp is expressed in the small intestine to an extent no less than that in the kidney, the study was designed to investigate the possible effect of quinidine on the absorption and exsorption of digoxin in the rat intestine. Results from the everted sac study using different Pgp inhibitors and inducers support that digoxin is a substrate of Pgp in both jejunum and ileum. Plasma concentration of digoxin after intravenous administration increased 2-fold when 1 mg/hr quinidine was coinfused, whereas the amount that appeared in the intestinal lumen decreased by approximately 40%. In the presence of quinidine, total clearance decreased from 318.0 +/- 19.3 to 167.1 +/- 11.0 ml/hr, whereas intestinal clearance decreased from 28.8 +/- 1.7 to 11.1 +/- 1.6 ml/hr. In a separate study, 3H-labeled digoxin was infused intravenously together with luminal perfusion of unlabeled digoxin in the intestine. The change of 3H-labeled digoxin concentrations in plasma and in the intestinal lumen was similar to those in the exsorption study. However, concentration of unlabeled digoxin in plasma or the intestinal lumen did not alter significantly with the addition of quinidine. The absorption clearance in the control group (N = 6, 6.4 +/- 0.47 ml/hr) was significantly higher than that in the group with quinidine coadministration (N = 6, 4.8 +/- 0.31 ml/hr; p < 0.05). This indicates that quinidine may affect not only the elimination of digoxin, such as renal secretion, but also the absorption/exsorption of digoxin in the gastrointestinal tract. This study suggests that Pgp is involved in the drug interaction between digoxin and quinidine in the small intestine. It is clinically important to understand the effect of quinidine on digoxin absorption for further assessment.
地高辛 - 奎尼丁相互作用在文献中有充分记载。然而,其机制尚不清楚。此前研究表明,奎尼丁通过抑制肾小管中的P - 糖蛋白(Pgp)来减少地高辛的分泌。由于Pgp在小肠中的表达程度不亚于在肾脏中的表达,因此本研究旨在探究奎尼丁对大鼠肠道中地高辛吸收和外排的可能影响。使用不同Pgp抑制剂和诱导剂的外翻肠囊研究结果支持地高辛在空肠和回肠中均为Pgp的底物。静脉注射地高辛时,当同时输注1mg /小时的奎尼丁,血浆浓度增加了2倍,而肠腔中出现的量减少了约40%。在有奎尼丁存在的情况下,总清除率从318.0±19.3降至167.1±11.0ml /小时,而肠道清除率从28.8±1.7降至11.1±1.6ml /小时。在另一项研究中,将3H标记的地高辛与未标记的地高辛在肠道内进行管腔灌注同时静脉输注。血浆和肠腔中3H标记的地高辛浓度变化与外排研究中的变化相似。然而,添加奎尼丁后,血浆或肠腔中未标记地高辛的浓度没有显著改变。对照组(N = 6,6.4±0.47ml /小时)的吸收清除率显著高于联合使用奎尼丁的组(N = 6,4.8±0.31ml /小时;p <0.05)。这表明奎尼丁不仅可能影响地高辛的消除,如肾脏分泌,还可能影响地高辛在胃肠道中的吸收/外排。本研究表明,Pgp参与了小肠中地高辛与奎尼丁之间的药物相互作用。了解奎尼丁对地高辛吸收的影响对于进一步评估具有重要的临床意义。